Clinical Trials Browser

Has results × cabozantinib × Genitourinary × Clear all

NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2 Active not recruiting

109 enrolled 24 charts

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT03945773 2026-03-13

CaboPoint

Phase 2 Completed

127 enrolled 17 charts

Carcinoma, Renal Cell

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT04022343 2026-01-05

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Phase 2 Active not recruiting

22 enrolled 16 charts

Carcinoma, Renal Cell

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 2 FDA

Carcinoma, Renal Cell

NCT04804813 2025-04-11

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

388 enrolled 20 charts

Carcinoma, Renal Cell

NCT03149822 2025-03-13

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Phase 1/2 Completed

45 enrolled 17 charts

Carcinoma, Renal Cell

NCT02761057 2025-01-13

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Phase 2 Completed

152 enrolled 19 charts

Carcinoma, Renal Cell

NCT03534804 2024-11-26

PemCab

Phase 2 Completed

37 enrolled 27 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2 Completed

730 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03428217 2023-03-20

CANTATA

Phase 2 Completed

444 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

NCT03964337 2022-06-29

SPARC

Phase 2 Terminated

3 enrolled 5 charts

Prostatic Neoplasms

NCT01630590 2022-03-25

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Phase 2 Completed

62 enrolled 15 charts

Prostatic Neoplasms

NCT01812668 2021-08-05

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Phase NA Completed

20 enrolled 12 charts

Prostatic Neoplasms

NCT01865747 2021-04-27

METEOR

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

NCT01835158 2021-02-11

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Phase 2 Completed

157 enrolled 10 charts 2 FDA

Carcinoma, Renal Cell

NCT01588821 2020-09-29

Cabozantinib in Advanced Solid Malignancies

Phase 2 Completed

37 enrolled 10 charts

GenitourinaryThoracic

Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence

NCT01599793 2020-03-26

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Phase 2 Completed

19 enrolled 11 charts

Prostatic Neoplasms

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Phase 1/2 Completed

49 enrolled 18 charts

Prostatic Neoplasms

NCT01703065 2018-12-04

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Phase 2 Terminated

9 enrolled 10 charts

Prostatic Neoplasms

NCT01522443 2018-05-23

COMET-2

Phase 3 Terminated

119 enrolled 21 charts

Pain, Prostatic Neoplasms

NCT01605227 2018-03-14

COMET-1

Phase 3 Completed

1,028 enrolled 18 charts

Pain, Prostatic Neoplasms

NCT01834651 2017-09-27

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Phase 2 Completed

17 enrolled 11 charts

Prostatic Neoplasms

NCT01347788 2016-11-28

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Phase 1 Completed

34 enrolled 6 charts

Prostatic Neoplasms